Xeris Pharmaceuticals Inc. (NASDAQ:XERS) has a beta value of 0 and has seen 2,211,388 shares traded in the last trading session. The company, currently valued at $254Million, closed the last trade at $3.83 per share which meant it lost -$0.04 on the day or -1.03% during that session. The XERS stock price is -107.31% off its 52-week high price of $7.94 and 59.27% above the 52-week low of $1.56. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.03 Million shares traded. The 3-month trading volume is 2.8 Million shares.
The consensus among analysts is that Xeris Pharmaceuticals Inc. (XERS) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 4 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.34.
Xeris Pharmaceuticals Inc. (NASDAQ:XERS) trade information
Despite being -1.03% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, Apr 26 when the XERS stock price touched $4.11-6 or saw a rise of 6.81%. Year-to-date, Xeris Pharmaceuticals Inc. shares have moved -22.15%, while the 5-day performance has seen it change -4.25%. Over the past 30 days, the shares of Xeris Pharmaceuticals Inc. (NASDAQ:XERS) have changed -9.03%. Short interest in the company has seen 13.56 Million shares shorted with days to cover at 4.84.
Wall Street analysts have a consensus price target for the stock at $11.25, which means that the shares’ value could jump 193.73% from current levels. The projected low price target is $9 while the price target rests at a high of $14. In that case, then, we find that the current price level is +265.54% off the targeted high while a plunge would see the stock lose 134.99% from current levels.
Xeris Pharmaceuticals Inc. (XERS) estimates and forecasts
Figures show that Xeris Pharmaceuticals Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -21.68% over the past 6 months, with this year growth rate of 48.6%, compared to 16.6% for the industry. Other than that, the company has, however Increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 61.8% and 52.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be +126%.
4 analysts offering their estimates for the company have set an average revenue estimate of $7.47 Million for the current quarter. 4 have an estimated revenue figure of $9.52 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $1.79 Million and $1.86 Million respectively for this quarter and the next, and analysts expect sales will grow by 317.8% for the current quarter and 411.8% for the next.
Earnings growth for 2021 is a modest +55.6%.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Xeris Pharmaceuticals Inc. (NASDAQ:XERS)’s Major holders
Insiders own 2.17% of the company shares, while shares held by institutions stand at 50.38% with a share float percentage of 51.5%. Investors are also buoyed by the number of investors in a company, with Xeris Pharmaceuticals Inc. having a total of 132 institutions that hold shares in the company. The top two institutional holders are Sessa Capital IM, L.P. with over 4.17 Million shares worth more than $20.53 Million. As of December 30, 2020, Sessa Capital IM, L.P. held 6.98% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 3.65 Million shares as of December 30, 2020. The firm’s total holdings are worth over $17.94 Million and represent 6.1% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Invesco Oppenheimer Global Opportunities Fund and Vanguard Total Stock Market Index Fund. As of January 30, 2021, the former fund manager holds about 3.35% shares in the company for having 2000000 shares of worth $10.16 Million while later fund manager owns 1.32 Million shares of worth $6.49 Million as of December 30, 2020, which makes it owner of about 2.21% of company’s outstanding stock.